The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Megace     [(8R,9S,10R,13S,14S,17R)-17- ethanoyl-6,10...

Synonyms: Magestin, Megeron, Niagestin, Pallace, Ovaban, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Megestat


High impact information on Megestat

  • Nutritional status and parameters of body composition were compared in the Megace and non-Megace-treated subjects [6].
  • No 3H-DHT binding to a cytosol receptor protein could be demonstrated in 4 out of 5 prostates from Megace-treated patients, whereas the presence of such a receptor was noted in 14 out of 17 untreated controls [2].
  • In addition to these effects on tissue, Megace significantly decreased plasma levels of T, LH, and FSH at the end of the 4- to 25-day period; plasma prolactin levels did not change [2].
  • Appetite stimulants such as Megace Oral Suspension (Bristol-Myers Squibb, Princeton, NJ) are used not so much for facilitating weight gain as for adding to the quality of life, including social and psychological well-being, by allowing patients to enjoy foods they like in a social family setting [7].
  • The ventral prostates of the flutamide and RU23908 groups were similar and reduced 75% and 85% at 14 and 28 days respectively; the group receiving megace experienced prostatic regression of 49% and 65% which was significantly less of a reduction than that of the flutamide or RU23908 group [8].

Chemical compound and disease context of Megestat


Biological context of Megestat

  • Thirteen patients with advanced pancreatic carcinoma were treated with circadian rhythm modulated infusion of 5-FUdR and Megace [13].

Associations of Megestat with other chemical compounds


Gene context of Megestat


Analytical, diagnostic and therapeutic context of Megestat

  • Twenty-nine patients received no postoperative treatment, 2 received chemotherapy, 3 received Megace, and 9 received radiation therapy [18].
  • Two patients received radiation, three adjuvant chemotherapy, two hormonal therapy (Megace 160 mg qd), three received no therapy at all, and the treatment is not known in one case [19].
  • Eighteen postmenopausal patients were randomly distributed over six groups to receive daily 90, 180 or 270 mg of MA (niagestin) orally in a cross-over study consisting of 3 periods of 6 weeks [20].


  1. Megace and no diabetes mellitus. Ansfield, F.J. Ann. Intern. Med. (1977) [Pubmed]
  2. Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate. Geller, J., Albert, J., Geller, S., Lopez, D., Cantor, T., Yen, S. J. Clin. Endocrinol. Metab. (1976) [Pubmed]
  3. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). Thürlimann, B., Castiglione, M., Hsu-Schmitz, S.F., Cavalli, F., Bonnefoi, H., Fey, M.F., Morant, R., Löhnert, T., Goldhirsch, A. Eur. J. Cancer (1997) [Pubmed]
  4. Megace for AIDS cachexia: food for thought. Novak, J., Barkin, J.S. Am. J. Gastroenterol. (1995) [Pubmed]
  5. Single-agent/combination therapy of human immunodeficiency virus-related wasting. Wanke, C. Semin. Oncol. (1998) [Pubmed]
  6. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. Grinspoon, S., Corcoran, C., Lee, K., Burrows, B., Hubbard, J., Katznelson, L., Walsh, M., Guccione, A., Cannan, J., Heller, H., Basgoz, N., Klibanski, A. J. Clin. Endocrinol. Metab. (1996) [Pubmed]
  7. Approach to the seriously ill or terminal cancer patient who has a poor appetite. Seligman, P.A., Fink, R., Massey-Seligman, E.J. Semin. Oncol. (1998) [Pubmed]
  8. Effectiveness of antiandrogens in the rat. Burton, S., Trachtenberg, J. J. Urol. (1986) [Pubmed]
  9. Effect of megestrol acetate and prepulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy. Chen, H.C., Leung, S.W., Wang, C.J., Sun, L.M., Fang, F.M., Hsu, J.H. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. (1997) [Pubmed]
  10. Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace. Scribner, D.R., Walker, J.L. Gynecol. Oncol. (1998) [Pubmed]
  11. Comparison of Megace, Stilphostrol, Megace plus DES, or streptozotocin in metastatic prostatic cancer in patients with hormonal failure and prior radiotherapy. McLeod, D.G., Murphy, G.P., Priore, R. Urology (1988) [Pubmed]
  12. Response of brain metastases from breast cancer to megestrol acetate: a case report. Stewart, D.J., Dahrouge, S. J. Neurooncol. (1995) [Pubmed]
  13. Circadian rhythm modulated 5-FUdR infusion with Megace in the treatment of advanced pancreatic cancer. Marsh, R.W., Manyam, V., Bewsher, C., Youngblood, M. Journal of surgical oncology. (1994) [Pubmed]
  14. Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue. Geller, J., Albert, J., Geller, S. Prostate (1982) [Pubmed]
  15. Whole-abdominal radiation in endometrial carcinoma: an analysis of toxicity, patterns of recurrence, and survival. Small, W., Mahadevan, A., Roland, P., Vallow, L., Zusag, T., Fishman, D., Massad, S., Rademaker, A., Kalapurakal, J.A., Chang, S., Lurain, J. Cancer journal (Sudbury, Mass.) (2000) [Pubmed]
  16. Effect of antiandrogen and/or antiestrogen blockade on human prostate epithelial and stromal cell protein synthesis. Geller, J., Liu, J., Albert, J., Fay, W., Berry, C.C. J. Steroid Biochem. (1986) [Pubmed]
  17. Abnormal ACTH-stimulation test in a patient with AIDS: adrenal insufficiency or toxoplasmosis? Koch, C.A., Pacak, K. Endocrine regulations. (2001) [Pubmed]
  18. Laparoscopic surgery does not increase the positive peritoneal cytology among women with endometrial carcinoma. Eltabbakh, G.H., Mount, S.L. Gynecol. Oncol. (2006) [Pubmed]
  19. Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors. Katz, L., Merino, M.J., Sakamoto, H., Schwartz, P.E. Gynecol. Oncol. (1987) [Pubmed]
  20. Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects. Alexieva-Figusch, J., Blankenstein, M.A., Hop, W.C., Klijn, J.G., Lamberts, S.W., de Jong, F.H., Docter, R., Adlercreutz, H., van Gilse, H.A. European journal of cancer & clinical oncology. (1984) [Pubmed]
WikiGenes - Universities